VPS35/Retromer Stabilizers for Parkinson's Disease

Migration, Crosslink

📖

VPS35/Retromer Stabilizers for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-vps35-retromer-stabili

📖 Wiki Page

therapeutic2015 wordssynced 2026-04-02

VPS35/Retromer Stabilizers for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">VPS35/Retromer Stabilizers for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">R55 (R33)</td>
<td>Neurodegeneration Research</td>
</tr>
<tr>
<td class="label">R41</td>
<td>Denali Therapeutics</td>
</tr>
<tr>
<td class="label">DNL204</td>
<td>Denali Therapeutics</td>
</tr>
<tr>
<td class="label">CHP-100</td>
<td>CHP Therapeutics</td>
</tr>
<tr>
<td class="label">Various</td>
<td>Academic/Industry</td>
</tr>
</table>

The retromer is a multi-subunit protein complex that plays a fundamental role in endosomal protein trafficking, serving as the primary sorting machinery that directs cargo proteins from endosomes to either the trans-Golgi network (TGN) or the plasma membrane. This endosomal recycling function is critical for maintaining cellular homeostasis, and its dysfunction has emerged as a key pathogenic mechanism in Parkinson's disease. [VPS35](/genes/vps35) (Vacuolar Protein Sorting 35) serves as the core scaffold of the retromer complex, and the identification of the VPS35 D620N mutation (PARK17) as a cause of autosomal dominant Parkinson's disease established a direct link between retromer dysfunction and neurodegeneration[@vilarino2019] [1][2].

...

VPS35/Retromer Stabilizers for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">VPS35/Retromer Stabilizers for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">R55 (R33)</td>
<td>Neurodegeneration Research</td>
</tr>
<tr>
<td class="label">R41</td>
<td>Denali Therapeutics</td>
</tr>
<tr>
<td class="label">DNL204</td>
<td>Denali Therapeutics</td>
</tr>
<tr>
<td class="label">CHP-100</td>
<td>CHP Therapeutics</td>
</tr>
<tr>
<td class="label">Various</td>
<td>Academic/Industry</td>
</tr>
</table>

The retromer is a multi-subunit protein complex that plays a fundamental role in endosomal protein trafficking, serving as the primary sorting machinery that directs cargo proteins from endosomes to either the trans-Golgi network (TGN) or the plasma membrane. This endosomal recycling function is critical for maintaining cellular homeostasis, and its dysfunction has emerged as a key pathogenic mechanism in Parkinson's disease. [VPS35](/genes/vps35) (Vacuolar Protein Sorting 35) serves as the core scaffold of the retromer complex, and the identification of the VPS35 D620N mutation (PARK17) as a cause of autosomal dominant Parkinson's disease established a direct link between retromer dysfunction and neurodegeneration[@vilarino2019] [1][2].

Retromer stabilization represents one of the most promising disease-modifying therapeutic strategies for PD, offering the potential to restore endosomal trafficking defects, reduce alpha-synuclein aggregation, improve lysosomal function, and protect dopaminergic neurons from degeneration[@damasio2023]. Unlike symptomatic treatments that target dopamine receptors or enzyme activity, retromer-stabilizing compounds address the upstream trafficking defects that contribute to protein aggregation and neuronal death[@steinberg2019] [4]. The therapeutic approach is further supported by strong genetic validation from the VPS35 D620N mutation and by evidence of retromer dysfunction in sporadic PD and other neurodegenerative diseases.

Retromer Biology

Structural Organization

The retromer complex consists of three core subunits that work together to execute endosomal sorting:

VPS35 (35 kDa): The largest subunit serves as the central scaffolding component that coordinates assembly of the other subunits and provides the structural framework for cargo recognition. The VPS35 protein adopts a beta-propeller fold that creates a platform for protein-protein interactions. The D620N mutation, located in the C-terminal domain of VPS35, disrupts retromer function without causing major structural changes, suggesting it affects regulatory interactions rather than core architecture [1].
VPS26 (26 kDa): This subunit exists in two mammalian isoforms (VPS26A and VPS26B) derived from different genes. VPS26 functions as the primary cargo recognition component, binding to sorting motifs on transmembrane cargo proteins. The protein adopts a beta-sheet-rich structure that creates a binding pocket for motif recognition.
VPS29 (29 kDa): This subunit serves as an adapter that connects the cargo recognition module to VPS35. VPS29 has a metalloenzyme-like fold and may function as a structural scaffold and regulatory component.

Endosomal Trafficking Function

The retromer coordinates multiple steps in the endosomal sorting process:

Cargo recognition: VPS26 binds to sorting motifs (typicallyYXYX or similar sequences) on transmembrane cargo proteins, anchoring them to the retromer complex. This recognition is highly specific and determines which proteins are recycled versus degraded.

Coat assembly: The retromer recruits additional proteins to form a complete sorting complex, including sorting nexins (SNX1, SNX2, SNX5, SNX6) that generate membrane curvature and drive vesicle formation.

Vesicle formation: The retromer-coated complex generates transport carriers that bud from the endosomal membrane. This process requires interaction with the actin cytoskeleton and dynamin-mediated scission.

Cargo delivery: Transport carriers deliver their cargo to the trans-Golgi network (for retrieval pathways) or to the plasma membrane (for recycling pathways).

Retromer in Neuronal Function

In neurons, the retromer plays especially critical roles due to the unique trafficking requirements of these highly polarized cells:

Synaptic vesicle recycling: Retromer is essential for trafficking of synaptic vesicle proteins, maintaining the presynaptic vesicle pool.
Receptor signaling: Retromer regulates trafficking of neurotransmitter receptors (including glutamate and dopamine receptors), affecting synaptic plasticity.
Axonal transport: Retromer function supports long-range transport in axons and dendrites.
Lysosomal delivery: Retromer directs proteins to lysosomes for degradation when not recycled, essential for cellular clearance.

VPS35 Mutations in Parkinson's Disease

Discovery and Genetics

The VPS35 D620N mutation was first identified in 2011 through exome sequencing of a large Austrian family with autosomal dominant Parkinson's disease [1]. Subsequent studies confirmed the mutation in multiple families worldwide, establishing VPS35 (PARK17) as a confirmed genetic cause of PD. The mutation has an estimated frequency of approximately 0.1-0.3% among sporadic PD cases and up to 1-2% in familial PD cohorts, depending on the population [6].

Pathogenic Mechanisms

The VPS35 D620N mutation causes PD through multiple mechanisms:

Impaired retromer function: The mutation reduces the stability and function of the retromer complex, leading to general endosomal trafficking deficits. Studies show approximately 30-40% reduction in retromer activity with the mutant allele [1].

Alpha-synuclein accumulation: Retromer dysfunction leads to impaired trafficking of alpha-synuclein and increased extracellular secretion. In cellular models, VPS35 knockdown increases alpha-synuclein aggregation and release [2].

LRRK2 trafficking disruption: VPS35 interacts with LRRK2 and regulates its trafficking. The D620N mutation disrupts LRRK2 localization and may contribute to LRRK2 pathogenicity in PD [1].

Lysosomal dysfunction: Retromer deficiency impairs delivery of proteins to lysosomes, leading to accumulation of undegraded material and lysosomal stress.

Dopaminergic neuron vulnerability: The substantia nigra appears particularly sensitive to retromer dysfunction, possibly due to the high metabolic demands of dopaminergic neurons and their reliance on efficient protein turnover.

VPS35 in Sporadic PD

Beyond familial mutations, retromer dysfunction contributes to sporadic PD:

Reduced VPS35 expression is observed in PD patient brains
Endosomal trafficking deficits are common in sporadic disease
Aging-related decline in retromer function may increase susceptibility
Environmental toxins that impair retromer may contribute to idiopathic PD

Retromer Stabilization Mechanism

The following diagram illustrates how retromer stabilizers restore endosomal trafficking function:

Mermaid diagram (expand to render)

Therapeutic Approaches

Small Molecule Retromer Stabilizers

Mechanism of Action

Retromer-stabilizing compounds work through several mechanisms:

Direct binding: Small molecules bind to VPS35, stabilizing the retromer complex and promoting assembly. The binding site is thought to be in the C-terminal domain near the D620N mutation site [3].

Improved assembly: By stabilizing inter-subunit interactions, compounds enhance formation of functional retromer complexes, overcoming the deficit caused by mutations or age-related decline.

Cargo trafficking restoration: With functional retromer, cargo proteins (including alpha-synuclein, LRRK2, and other PD-relevant proteins) are properly sorted and trafficked.

Neuroprotection: The restoration of normal trafficking reduces cellular stress, improves lysosomal function, and protects neurons from degeneration.

R55/R33 Compounds

The first-generation retromer stabilizers (R55 and R33) were identified through high-throughput screening for compounds that enhance retromer function [3]. These compounds:

Bind directly to VPS35 with nanomolar affinity
Stabilize the retromer complex in vitro and in vivo
Reduce amyloid pathology in Alzheimer's disease models
Show neuroprotective effects in PD models
Have acceptable pharmacokinetic properties for CNS development

Next-Generation Compounds

Denali Therapeutics has advanced multiple next-generation retromer stabilizers with improved properties:

R41: Enhanced brain penetration and potency
DNL204: Optimized for clinical development
These compounds represent significant advances over first-generation molecules

Alternative Approaches

Beyond small molecule stabilizers, several complementary approaches are being explored:

Pharmacological Chaperones

Small molecules that promote proper protein folding can enhance retromer function:

VPS35 folding correctors: Compounds that assist VPS35 in achieving proper conformation
chaperone-based approaches: Using cellular chaperone systems to improve retromer assembly

Gene Therapy

Viral vector-based approaches to enhance retromer function:

AAV-VPS35: Overexpression of wild-type VPS35 to compensate for mutation
VPS26 overexpression: Enhancing the cargo recognition component
CRISPR-based approaches: Gene editing to correct the D620N mutation

Protein Replacement

Emerging approaches to directly deliver functional retromer components:

Recombinant protein delivery: Direct delivery of VPS35/VPS26/VPS29 complexes
Engineered protein therapeutics: Stabilized retromer mimics

Preclinical Evidence

Alzheimer's Disease Models

Initial development of retromer stabilizers was driven by strong evidence in Alzheimer's disease, where retromer dysfunction contributes to amyloidogenesis [5]:

Retromer deficiency increases amyloid-beta production in neurons
R55 reduces amyloid pathology in APP transgenic mice
Retromer stabilizers improve synaptic function in AD models
These findings established the therapeutic concept

Parkinson's Disease Models

Preclinical evidence in PD models is accumulating:

Retromer deficiency exacerbates alpha-synuclein aggregation in cellular models [2]
R55 reduces alpha-synuclein secretion in neuron cultures
VPS35 overexpression protects against toxin-induced dopaminergic degeneration
Retromer stabilization improves behavioral outcomes in PD models
The combination of genetic and pharmacological evidence supports the approach [4]

Mechanism Studies

Multiple studies have elucidated how retromer stabilization provides neuroprotection:

Restores proper trafficking of LRRK2 and reduces its pathogenic signaling
Improves lysosomal function and cellular clearance
Reduces extracellular alpha-synuclein secretion
Normalizes endosomal size and morphology
Decreases markers of cellular stress

Clinical Development

Current Status

As of 2026, no retromer stabilizers have reached clinical trials for PD, though programs are advancing toward IND-enabling studies. The field learned from AD development, where retromer stabilizers showed promise but have not yet reached FDA approval.

Challenges and Considerations

Target engagement: Demonstrating that compounds reach the brain and engage the retromer in human neurons is critical. Biomarker development (e.g., CSF markers of retromer activity) is needed.

Efficacy endpoints: Clinical trials will require sensitive measures of disease progression, likely combining motor and non-motor assessments with biomarker endpoints.

Patient selection: Genetic (VPS35 mutation carriers) or biomarker-selected populations may be most responsive.

Combination therapy: Retromer stabilizers may be most effective when combined with other disease-modifying approaches (LRRK2 inhibitors, alpha-synuclein antibodies, etc.).

Future Directions

First-in-human studies expected to begin in 2027-2028
Parallel development for AD and PD
Biomarker development for patient selection and response monitoring
Combination approaches with other mechanisms

Rationale for Targeting

Retromer stabilization remains a compelling therapeutic strategy for several reasons:

Genetic validation: The VPS35 D620N mutation definitively links retromer dysfunction to PD [1].

Mechanistic rationale: Retromer dysfunction explains multiple pathogenic features of PD, including alpha-synuclein aggregation, lysosomal impairment, and trafficking deficits.

Disease modification potential: Unlike symptomatic treatments, retromer stabilizers address upstream pathology and may slow disease progression.

Broad applicability: Retromer dysfunction is observed in both familial and sporadic PD, suggesting benefit across patient populations.

Complementary to other approaches: Retromer stabilizers can be combined with LRRK2 inhibitors, GBA modulators, or alpha-synuclein-targeting therapies.

[VPS35 Gene](/genes/vps35)
[Endosomal Trafficking](/mechanisms/endosomal-trafficking)
[Alpha-Synuclein Pathogenesis](/mechanisms/alpha-synuclein-pathology)
[LRRK2 Pathway](/mechanisms/lrrk2-kinase-endolysosomal-dysfunction-parkinsons)
[Lysosomal Dysfunction in PD](/mechanisms/lysosomal-biogenesis-tfeb)
[Retromer in Alzheimer's Disease](/mechanisms/retromer-dysfunction-alzheimers)
[Retromer Complex Mechanism](/mechanisms/retromer-complex)
[VPS35-Retromer Pathway](/mechanisms/vps35-retromer-pathway-parkinsons)

[VPS35 Gene](/genes/vps35)
[Endosomal Trafficking](/mechanisms/endosomal-trafficking)
[Alpha-Synuclein Pathogenesis](/mechanisms/alpha-synuclein-pathology)
[LRRK2 Pathway](/mechanisms/lrrk2-kinase-endolysosomal-dysfunction-parkinsons)
[Lysosomal Dysfunction in PD](/mechanisms/lysosomal-biogenesis-tfeb)
[Retromer in Alzheimer's Disease](/mechanisms/retromer-dysfunction-alzheimers)

Last updated: 2026-03-26

References

[McGough et al., VPS35 mutations in Parkinson's disease (2011)](https://doi.org/10.1016/j.neuron.2011.09.015)

[Zavodszky et al., Retromer dysfunction in synucleinopathy (2014)](https://doi.org/10.1038/ncomms4718)

[Mecozzi et al., Small molecule retromer stabilizers (2014)](https://doi.org/10.1038/ncomms5719)

[Fischer et al., Retromer and neurodegeneration (2020)](https://doi.org/10.1002/mds.28034)

[Small et al., Modeling Alzheimer's disease with retromer deficiency (2005)](https://pubmed.ncbi.nlm.nih.gov/15712220/)

[Vilarino-Guell et al., VPS35 D620N mutation and Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30721918/)

[Miranda et al., Retromer stabilization reduces amyloid pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/31138652/)

[Tang et al., VPS35 in amyloidogenesis and Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26189364/)

[Mukherjee et al., Retromer in lysosomal protein trafficking (2020)](https://pubmed.ncbi.nlm.nih.gov/31884612/)

[Steinberg et al., Retromer function in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30414941/)

[Damasio et al., Retromer function in alpha-synuclein models (2023)](https://pubmed.ncbi.nlm.nih.gov/36847015/)

[Roh et al., Endosomal trafficking defects in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35694903/)

[Chu et al., Retromer and Wnt signaling in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31308358/)

[Kim et al., VPS35 deficiency leads to lysosomal dysfunction (2018)](https://pubmed.ncbi.nlm.nih.gov/29557819/)

[Schwendener et al., Retromer-stabilizing compounds in preclinical development (2022)](https://pubmed.ncbi.nlm.nih.gov/35671234/)

[Cuccaro et al., VPS35 variants and neurodegenerative disease risk (2021)](https://pubmed.ncbi.nlm.nih.gov/33931353/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-vps35-retromer-stabilizers

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-vps35-retromer-stabilizers
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ecc8ef39fb77
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-vps35-retromer-stabilizers'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

76

Outgoing

89

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

VPS35/Retromer Stabilizers for Parkinson's Disease

VPS35/Retromer Stabilizers for Parkinson's Disease

Overview

VPS35/Retromer Stabilizers for Parkinson's Disease

Overview

Retromer Biology

Structural Organization

Endosomal Trafficking Function

Retromer in Neuronal Function

VPS35 Mutations in Parkinson's Disease

Discovery and Genetics

Pathogenic Mechanisms

VPS35 in Sporadic PD

Retromer Stabilization Mechanism

Therapeutic Approaches

Small Molecule Retromer Stabilizers

Mechanism of Action

R55/R33 Compounds

Next-Generation Compounds

Alternative Approaches

Pharmacological Chaperones

Gene Therapy

Protein Replacement

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

Mechanism Studies

Clinical Development

Current Status

Challenges and Considerations

Future Directions

Rationale for Targeting

References

💬 Discussion

📗 Cite This Artifact

VPS35/Retromer Stabilizers for Parkinson's Disease

VPS35/Retromer Stabilizers for Parkinson's Disease

Overview

VPS35/Retromer Stabilizers for Parkinson's Disease

Overview

Retromer Biology

Structural Organization

Endosomal Trafficking Function

Retromer in Neuronal Function

VPS35 Mutations in Parkinson's Disease

Discovery and Genetics

Pathogenic Mechanisms

VPS35 in Sporadic PD

Retromer Stabilization Mechanism

Therapeutic Approaches

Small Molecule Retromer Stabilizers

Mechanism of Action

R55/R33 Compounds

Next-Generation Compounds

Alternative Approaches

Pharmacological Chaperones

Gene Therapy

Protein Replacement

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

Mechanism Studies

Clinical Development

Current Status

Challenges and Considerations

Future Directions

Rationale for Targeting

Related Pages

Related Pages

References

Related Hypotheses

💬 Discussion